Surgery risks after immunotherapy for liver cancer
Part of Cancer, Digestive system clinical trials.
This study looks at the risks of surgery in people with liver cancer who received immunotherapy before or instead of surgery. It aims to understand how safe and effective this approach is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have liver cancer (HCC) that was confirmed by biopsy or imaging.
- You must have received immunotherapy before or instead of surgery, and then had surgery within the last 4 weeks.
- Your liver function must be good (Child-Pugh score A or B) and you should be able to care for yourself (ECOG score 0-1).
- You cannot have other active cancers (except for certain skin or cervical cancers) or serious heart, lung, or bleeding problems.
- If you have hepatitis B or C, you must be willing to take antiviral medication during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy (atezolizumab) before liver surgery helps your body fight liver cancer more effectively. It's for people with early-stage liver cancer who are already scheduled for surgery.
This trial tests immunotherapy-based combinations for liver cancer. It may help if your doctor thinks this treatment could benefit you.
This trial tests whether combining the immunotherapy drug sintilimab with targeted radiation therapy before surgery can improve outcomes for patients with liver cancer that can be surgically removed. It aims to shrink the tumor and reduce the chance of recurrence.
This trial tests giving two immunotherapy drugs directly into the tumor before surgery for liver cancer. It aims to see if this approach can shrink the tumor and improve outcomes for patients who are candidates for surgery.
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
This study tests whether combining two immunotherapy drugs (sintilimab and ipilimumab) with standard procedures to block or destroy the tumor's blood supply can help keep liver cancer from returning after surgery. It is for people whose liver cancer can be removed but has a higher risk of coming back.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.